FDA approves Zepatier for treatment of chronic HCV GT1 and GT4
29 January 2016 | By Victoria White
Zepatier is a once-daily, fixed-dose combination tablet containing the NS5A inhibitor elbasvir and the NS3/4A protease inhibitor grazoprevir...
List view / Grid view
News
EC approves Daklinza in three new HCV patient populations
29 January 2016 | By Victoria White
The expanded label allows for the use of Daklinza (daclatasvir) in combination with sofosbuvir in HCV patients with decompensated cirrhosis, HIV-1 coinfection, and post-liver transplant recurrence of HCV...
Patient recruitment starts for MERS vaccine trial
28 January 2016 | By Victoria White
Inovio and GeneOne Life Science are co-developing Inovio’s MERS vaccine (GLS-5300) in partnership with the Walter Reed Army Institute of Research...
EC approves two new indications for Lilly’s ramucirumab
28 January 2016 | By Victoria White
The European Commission has approved two new indications for Lilly’s Cyramza (ramucirumab): one in patients with NSCLC and the other in patients with mCRC...
B-cell NHL treatment market to reach $5.45 billion by 2024, says GlobalData
28 January 2016 | By Victoria White
GlobalData states that the limited growth in the B-cell NHL treatment market will be hindered by the entry of biosimilars and generics combined with a weak pipeline...
FDA grants Breakthrough Therapy designation to Lynparza in mCRPC
28 January 2016 | By Victoria White
This Lynparza BTD is for the treatment of BRCA1/2 or ATM gene mutated metastatic Castration Resistant Prostate Cancer...
FDA grants third venetoclax Breakthrough Therapy Designation
28 January 2016 | By Victoria White
The designation is for venetoclax in combination with HMAs for the treatment of patients with untreated AML who are ineligible to receive standard induction therapy...
STRIVE results for enzalutamide in CRPC published
27 January 2016 | By Victoria White
The study achieved its primary endpoint demonstrating a statistically significant increase in PFS for enzalutamide compared with bicalutamide...
FDA to review BLA for Merck’s bezlotoxumab
27 January 2016 | By Victoria White
Bezlotoxumab is designed to neutralize C. difficile toxin B, a toxin that can damage the gut wall and cause inflammation, leading to C. difficile-associated diarrhoea...
Cosentyx to achieve blockbuster status
27 January 2016 | By Victoria White
Alexandra Annis states that Cosentyx's latest approval will bring exciting new treatment options to US patients dissatisfied with current therapies...
Presentation videos from the World’s 1st International Pharmaceutical seminar on Transmission Raman Spectroscopy available online
27 January 2016 | By Colbalt Light System
Videos of the presentations from the world’s 1st TRS seminar for quantitative pharmaceutical analysis can be viewed on demand...
NICE recommends five new therapies
27 January 2016 | By Victoria White
NICE has published its final recommendations on whether six different drug treatments should be routinely funded by the NHS...
Afatinib demonstrates superior PFS to gefitinib in NSCLC trial
27 January 2016 | By Victoria White
Results from the LUX-Lung 7 trial demonstrated superiority in progression-free survival and time to treatment failure with Boehringer Ingelheim’s Giotrif/Gilotrif (afatinib) versus Iressa (gefitinib)...
NICE recommends 7 DMARDs for severe rheumatoid arthritis
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
Epilepsy drug shows promise in protecting nerves from damage in MS
26 January 2016 | By Victoria White
Researchers from UCL found the anti-convulsant drug phenytoin protected neural tissue in patients with optic neuritis - often the first symptom of MS...
